XATOA – Xarelto + Acetylsalicylic Acid: Treatment
| abstract |
The study aims to collect real-world data on treatment patterns and decision points for treatment in patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) treated with rivaroxaban 2.5 mg[BID] for the prevention of atherothrombotic events in adult patients at high risk of ischaemic events and to describe outcomes of an antithrombotic regime based on dual pathway inhibition (vascular dose of rivaroxaban 2.5 mg [BID] plus low-dose ASA [OD]) across the broad range of patient risk profiles encountered in routine clinical practice. The primary objective in this study is: • to describe treatment patterns in CAD or PAD patients treated with rivaroxaban 2.5 mg [BID] plus ASA 75-100 mg [OD] in routine clinical practice |
| project homepage | http://https://clinicaltrials.gov/ct2/show/NCT03746275 |
| project partner | BAYER |
| type of project | clinical studies |
| status | completed |
| start of project | 2019 |
| end of project | 2021 |
| study design |
Observational Model: Cohort Time Perspective: Prospective |
| responsible person | Prof. Dr. Hans Rickli |